Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: Estimates from the multi-ethnic study of atherosclerosis

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 3, 2014, Pages 453-460

  Miedema, Michael D ^a,b   Duprez, Daniel A ^c   Misialek, Jeffrey R ^d   Blaha, Michael J ^e   Nasir, Khurram ^e,f,g,h   Silverman, Michael G ^e   Blankstein, Ron ⁱ   Budoff, Matthew J ^j   Greenland, Philip ^k   Folsom, Aaron R ^d  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Center for Prevention and Wellness   (United States)

^g FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^h FLORIDA INTERNATIONAL UNIVERSITY   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Aspirin; Coronary disease; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; FIBRINOLYTIC AGENT;

AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DRUG UTILIZATION; ETHNICITY; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; ISCHEMIC HEART DISEASE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; COMPLICATION; CORONARY BLOOD VESSEL; CORONARY DISEASE; ETHNIC GROUP; FOLLOW UP; HEMORRHAGE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; ATHEROSCLEROSIS; CALCIUM; CORONARY DISEASE; CORONARY VESSELS; ETHNIC GROUPS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84903612169     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000690     Document Type: Article

References (41)

1. Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njølstad I, Oganov R, Thomsen T, Tverdal A, Wedel H, Wilhelmsen L, Graham I; SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16:541-549.
2. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373:1849-1860.
3. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.
4. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162:115e2-124e2.
5. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209-216.
6. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation. 1993;88:2548-2555. (Pubitemid 23360179)
7. Miedema MD, Cohn JN, Garberich R, Henry J, Graham KJ, Henry TD. Under-use of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. Am Heart J. 2012;164:259-267.
8. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336-1345. (Pubitemid 351468410)
9. Blaha M, Budoff MJ, Shaw LJ, Khosa F, Rumberger JA, Berman D, Callister T, Raggi P, Blumenthal RS, Nasir K. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardiol. Cardiovasc Imaging. 2009;2:692-700.
10. Blankstein R, Budoff MJ, Shaw LJ, Goff DC Jr, Polak JF, Lima J, Blumenthal RS, Nasir K. Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58:364-374.
11. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610-1616.
12. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788-795.
13. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881. (Pubitemid 35215769)
14. The prevention of progression of arterial disease diabetes study group. The prevention of progression of arterial disease diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:1840.
15. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141.
16. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35-43. (Pubitemid 39658367)
17. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J. 1988;296:313-316. (Pubitemid 18042841)
18. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321:129-135.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)
20. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
21. De Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89-95.
22. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
23. Sussman JB, Vijan S, Choi H, Hayward RA. Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Circ Cardiovasc Qual Outcomes. 2011;4:268-275.
24. Aspirin for the Primary Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;150:396-404.
25. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
26. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation. 2002;106:388-391.
27. Effectiveness-based guidelines for the prevention of CVD in women-2011 update. A guideline from the American Heart Association. Circulation. 2011;123:1243-1262.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
29. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753. (Pubitemid 351640675)
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
31. Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O'Leary DH, Lima J, Blumenthal RS, Nasir K. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684-692.
32. Shaw LJ, Min JK, Budoff M, Gransar H, Rozanski A, Hayes SW, Friedman JD, Miranda R, Wong ND, Berman DS. Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study. J Am Coll Cardiol. 2009;54:1258-1267.
33. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press; 2009.
34. Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby JV, Udelson JE, Lauer MS. Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2012;60:569-580.
35. Whelton SP, Nasir K, Blaha MJ, Gransar H, Metkus TS, Coresh J, Berman DS, Blumenthal RS. Coronary artery calcium and primary prevention risk assessment: what is the evidence? An updated meta-analysis on patient and physician behavior. Circ Cardiovasc Qual Outcomes. 2012;5:601-607.
36. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:584-636.
37. Nasir K, Rubin J, Blaha MJ, Shaw LJ, Blankstein R, Rivera JJ, Khan AN, Berman D, Raggi P, Callister T, Rumberger JA, Min J, Jones SR, Blumenthal RS, Budoff MJ. Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. Circ Cardiovasc Imaging. 2012;5:467-473.
38. Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Hoffman U, Cury RC, Abbara S, Brady TJ, Budoff MJ, Blumenthal RS, Nasir K. Diagnostic and prognostic value of absence of coronary artery calcification. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:675-688.
39. Ambrosius WT, Polonsky TS, Greenland P, Goff DC Jr, Perdue LH, Fortmann SP, Margolis KL, Pajewski NM. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials. 2012;9:232-246.
40. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-848.
41. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286-2294.